Published Online
on
February 25, 2002
Circulation. 2002
Published online before print February 25, 2002,
doi: 10.1161/01.CIR.0000013090.96919.FA
A more recent version of this article appeared on March 19, 2002
© American Heart Association, Inc.
Maternal Hypercholesterolemia During Pregnancy Promotes Early Atherogenesis in LDL ReceptorDeficient Mice and Alters Aortic Gene Expression Determined by Microarray
Claudio Napoli, MD;
Filomena de Nigris, PhD;
John S. Welch, BS;
Federico B. Calara, PhD;
Robert O. Stuart, MD;
Christopher K. Glass, MD
Wulf Palinski, MD
From the Department of Medicine, University of California San Diego, La Jolla, Calif.
Correspondence to Wulf Palinski, MD, and Claudio Napoli, MD, Dept of Medicine, 0682 University of California, San Diego, 9500 Gilman Dr, MTF 110, La Jolla, CA 92093. E-mail wpalinski{at}ucsd.edu and cnapoli@ucsd.edu
 |
Abstract
|
|---|
Background Maternal hypercholesterolemia during pregnancy
is associated with markedly enhanced fatty streak formation
in human fetal aortas and accelerated progression of atherosclerosis
in normocholesterolemic children.
Methods and Results To establish the causal role of maternal hypercholesterolemia in a genetically homogeneous murine model and to test the hypothesis that pathogenic events during fetal development result in persistent changes in arterial gene expression, female LDL receptordeficient (LDLR-/-) mice were fed regular chow or high-fat diets supplemented with 0.075% or 1.25% cholesterol during pregnancy. Lesion sizes were determined in the aortic origin of their chow-fed offspring at 3 months. Maternal hypercholesterolemia more than doubled lesion sizes in male offspring (P<0.0001 for the 0.0075% cholesterol group). Microarray analysis of the expression of 11 000 murine genes in the nonatherosclerotic descending aorta by Affymetrix gene chips suggested that 139 genes were significantly regulated in offspring of hypercholesterolemic mothers. A subset of 12 of the upregulated transcripts was subjected to secondary analysis by semiquantitative PCR of pooled RNA and 4 genes were found to be upregulated >1.7-fold. Quantitative PCR for one of these genes using RNA from individual mice yielded similar results. Comparative immunostaining for several of the above genes also indicated increased protein content in offspring of hypercholesterolemic mothers.
Conclusions These findings establish an atherogenic effect of maternal hypercholesterolemia in genetically uniform mice and indicate that changes in aortic gene expression persist long after fetal exposure to hypercholesterolemia. In addition to elucidating pathogenic mechanisms initiated during fetal development, this approach may identify genes in morphologically normal arteries that influence the susceptibility to classical risk factors of atherosclerosis.
Key Words: atherosclerosis genes microarray pathology
 |
Introduction
|
|---|
Previous studies established that the atherogenic process in
humans may already begin during fetal development and that aortic
fatty streak formation at predilection sites of adult atherosclerosis
is greatly enhanced in fetuses of hypercholesterolemic mothers.
1,2 Although fetal plasma cholesterol levels markedly decrease toward
the end of pregnancy
1,3 and cholesterol levels during infancy
tend to be low, fetal lesions regress only partially and not
in all areas of the aorta.
4 Instead, the FELIC study (Fate of
Early Lesions in Children study, a morphometric postmortem analysis
of atherosclerosis in normocholesterolemic children aged 1 to
14 years) showed that maternal hypercholesterolemia was associated
with a much faster progression of atherosclerosis. This could
not be explained by conventional risk factors of atherosclerosis
in mothers or children. A number of theoretical considerations
also suggested that differences in the genetic background are
not the sole cause, even though genetic traits are likely to
contribute to fetal and postnatal atherogenesis.
4
Establishing a causal role of maternal/fetal hypercholesterolemia in accelerated fetal or postnatal lesion formation would not only add to our understanding of the pathogenesis of atherosclerosis, but can also have important clinical implications. Given the genetic heterogeneity of human populations and the variability in diets and classical risk factors, unequivocal evidence for a pathogenic role of maternal hypercholesterolemia in fetal lesion formation and enhanced susceptibility to postnatal atherogenesis could only be obtained in genetically more homogeneous experimental models.
A first line of evidence has recently been obtained in NZW rabbits.5,6 In this model, diet-induced maternal hypercholesterolemia was sufficient to enhance lesion formation in their offspring at birth, and both cholesterol-lowering and antioxidant interventions in mothers significantly reduced lesion sizes.5 Maternal hypercholesterolemia also markedly enhanced the postnatal atherogenic response to mild hypercholesterolemia, and treatment of mothers with antioxidants or lipid-lowering drugs effectively prevented this.6 These results establish, in principle, that maternal hypercholesterolemia or the ensuing pathogenic events during fetal development may accelerate atherogenesis later in life and suggest that interventions in hypercholesterolemic mothers during pregnancy may become a novel preventive approach. However, the mechanisms by which in utero programming enhances later atherogenesis are unknown.
The goal of this study was to establish a murine model of maternal hypercholesterolemia and to use it to test the hypothesis that pathogenic events during fetal development influence arterial gene expression later in life. Confirmation of the atherogenic effect of maternal hypercholesterolemia in a second model would greatly strengthen the assumption that maternal hypercholesterolemia contributes significantly to fetal lesion formation in humans. A murine model would also be particularly useful to investigate the underlying pathogenic mechanisms.7 We previously postulated that increased oxidative stress during fetal development would affect the expression of atherogenic factors in the arterial wall and that some of these differences would persist over time.4,6,8,9 This was based on the observation of markedly increased lipid peroxidation in plasma and lesions of mothers, fetuses, and newborns,1,2,5,6 and the fact that multiple signaling pathways are oxidation-sensitive.1016 The recent availability of murine cDNA microarrays assessing the expression of thousands of genes and expressed sequence tags (ESTs) at a time provides a tool to test this hypothesis and to identify genes that are differentially expressed.17,18
The present study provides evidence that maternal hypercholesterolemia indeed enhances early atherogenesis in genetically uniform mice and that changes in aortic gene expression in their offspring persist well beyond fetal development.
 |
Methods
|
|---|
Experimental Design
An overview of the experimental design is provided in
Figure 1 (top). Three groups of female LDL receptordeficient
(LDLR
-/-) mice (10th generation back-bred into C57BL6; from
our own breeding colony, established from animals originally
obtained from Jackson Labs, Bar Harbor, Me) were fed normal
chow or a standard high-fat diet (TD98338, Harlan-Teklad) supplemented
with 0.075% or 1.25% cholesterol, beginning 3 to 4 weeks before
pregnancy. The 1.25%, but not the 0.075% cholesterol diet, was
associated with reduced breeding success and litter sizes. Plasma
cholesterol and triglyceride levels were determined in blood
samples obtained from the retroorbital plexus, using an automated
enzymatic assay (Boehringer Mannheim Diagnostics). Because this
requires anesthesia, maternal TC was determined only prior to
the start of the diet and immediately before pregnancy, ie,
after 3 to 4 weeks on diet. At birth, hypercholesterolemic mothers
were switched to regular chow to reduce potential dietary effects
during lactation. Offspring were weaned after 3 to 4 weeks and
fed regular chow until the age of 3 months. Twelve male or female
progeny each of the "control", "0.075% cholesterol", or "1.25%
cholesterol" groups were used to determine atherogenesis in
the aortic origin and gene expression in the aorta. Note that
the group designation reflects maternal cholesterol status only,
not treatment after birth. Additional mice were used to assess
the presence of lesions in the aortic tree.

View larger version (49K):
[in this window]
[in a new window]
|
Figure 1. Experimental design. Insets: A, Representative photomicrograph of a cross-section through the aortic origin of a 3-month-old progeny of a control mother. Elastin in the muscular lining of the sinus of Valsalva is indicated by the red color. B, Higher magnification showing macrophage-rich early lesions underneath one of the aortic valve leaflets. C, Similar area in a mouse from the 1.25% cholesterol group. D, Expression level of all 139 significantly regulated genes and ESTs in the 3 experimental groups. Expression of each gene in the control group was defined as 1 and that in the 2 hypercholesterolemic groups indicated as relative expression. Intensity in the red color range indicates increasing upregulation; intensity in the blue range, increasing downregulation. A gene tree indicates clustering of genes behaving similarly. E, Line graph of the expression of all 139 significant genes and ESTs in the 3 experimental groups. Data for the control and 1.25% cholesterol groups represent the mean of 5 and 6 microarray determinations from various pools of the entire aorta or aortic segments, respectively, whereas data for the 0.075% cholesterol group represent a single balanced RNA pool of all 12 mice in this group.
|
|
LDLR-/- mice were used because the cholesterol level of the parent C57BL6 strain cannot be raised to and beyond that seen in human mothers by hypercholesterolemic diets, and because induction of even early fatty streaks in their aortic origin requires dietary supplementation with cholic acid, a proinflammatory agent that may affect genes expression.19 In contrast, in LDLR-/- mice cholate-free diets induce marked hypercholesterolemia and atherogenesis. However, plasma cholesterol levels of 250 mg/dL (expected in offspring fed regular chow) do not induce significant aortic lesion formation at 3 months of age.1921 Thus, under the present experimental conditions, offspring should have enough lesions in the aortic origin to permit one to assess atherogenic effects of maternal hypercholesterolemia, whereas atherogenesis in the aortic tree should be minimal. Hence, determination of aortic gene expression should not be affected by cellular heterogeneity resulting from the presence of various stages of lesions. Nevertheless, it should be kept in mind that our maternal control group was not normocholesterolemic by murine standards.
Tissue Preparation and Quantification of Atherosclerosis
At 3 months of age, offspring were euthanized by an overdose of anesthetic. Aortas were perfused for 10 minutes under physiological pressure with ice-cold RNAse-free phosphate-buffered saline, pH 7.4, through a canula inserted into the left ventricle. Tissue preparation and quantification of lesion sizes in the aortic origin were performed as described.20,22 Results are reported as mean lesion area per cross-section. The rest of the aorta was used to determine gene expression. Aortas were thoroughly cleaned of adventitial tissue in situ and divided into the arch, thoracic, and abdominal segments. Segments were blot-dried, flash-frozen, and stored in liquid nitrogen until further processing. To assess the absence or presence of lesions in the aortic tree, 2 entire aortas from each group were fixed, paraffin-embedded, and serially dissected from the heart to the iliac bifurcation. Every 10th section was stained with hematoxylin and eosin and examined microscopically.
Determination of Aortic Gene Expression by cDNA Microarray
Total tissue RNA was extracted using an RNeasy kit (QIAGEN) and determined by spectrophotometry. Double-stranded cDNA was synthesized using 50 ng of total RNA and an oligo dT primer with a T7 RNA polymerase promoter site added to its 3' end, following the protocol recommended by Affymetrix. The cDNA was then used for in vitro transcription in the presence of biotin-labeled ribonucleotides to yield biotin-labeled cRNA (Enzo Diagnostics kit). cRNA was cleaned using Qiagens RNeasy mini columns and protocols. RNA integrity was checked by 1% agarose gel electrophoresis and optical density determined at 260 and 280 nm. cRNA (15 µg) was then fragmented and used in a hybridization mix. An aliquot of the mix containing at least 10 µg cRNA was hybridized to the Affymetrix Mu11k subA and subB chips. Chips were then washed, stained, and scanned at the Veterans Affairs Medical Center Microarray Core unit directed by Dr Wachsman. A total of 12 Mu11k chip sets (subA and subB, each) were used to compare normo- and hypercholesterolemic groups and for comparisons between different arterial segments within groups. Pooled tissues of 3 mice each, as well as equally pooled samples of all mice in the 0.075% cholesterol and control groups, were used.
Polymerase Chain Reaction Analysis
Twelve genes exhibiting significant increases in the offspring of hypercholesterolemic mothers by microarray analysis were subjected to secondary analysis by semiquantitative polymerase chain reaction (PCR). For this experiment, the actual mRNA samples of the 0.075% cholesterol group (equal pool from the aortic arch of all 12 mice) and a corresponding sample from 9 control mice were used. Reverse transcription (RT)PCR was performed by converting 150 ng of total RNA to cDNA using oligo dT priming and SuperScipt RT (Life Technologies) as directed. cDNA was amplified in a 50-µL reaction containing 100 ng of each primer and 1xMaster Mix Taq polymerase (Qiagen). Cycle conditions were 94°C, 5 minutes; 45 cycles (94°C, 30 seconds; 58°C, 30 seconds; 72°C, 90 seconds); 72°C, 5 minutes; 4°C. Block temperature was decreased to 20°C and 5-µL aliquots taken after cycles 29, 32, 35, 38, 41, and 45. These were visualized by gel electrophoresis and quantitated using AlphaImager 2000 software (Alpha Innotech Corporation). Primers used were FGF-BP-1, 5'-ggtcagaaagagagccaagaac-3', 5'-atgtcgcctgtaacatgttgag-3'; FCMo3, 5'-gatgactttcccaacttcatgc-3', 5'-cttgagaaacagccataggaga-3'; NPAS2, 5'-tcacacacagccatgtcagaac-3', 5'-agatgttggtgcctgcaaatag-3'; and MERG1, 5'-tcctacaccaatggcatcgaca-3', 5'-actgggaaacctgagaaagcga-3'. Results were normalized to GAPDH. Due to the relatively high levels of GAPDH in these tissues, the cDNA was diluted 1:50 for the GAPDH measurements. Measurements were repeated 3 times.
Expression of one of the above genes, FCMo3, was also determined by quantitative PCR in all individual samples of the control and 0.075% cholesterol group in which sufficient RNA remained available. Competitor DNA was cloned into TOPO BluntII (Invitrogen) using the same primers as in subsequent PCR: GAPDH, 5'-ccagtatgactccactcacgg-3', 5'-cagtgggccctcagatgcctg-3'; FCMo3, 5'-gatgactttcccaacttcatgc-3', 5'-cttgagaaacagccataggaga-3'. To generate the competitor plasmid, 189 base pairs were removed from the GAPDH clone by digestion with AccI and EcoNI, followed by blunt end ligation. Likewise, the FCMo3 clone was digested with BstEII and ligated, removing 261 base pairs. Decreasing amounts of competitor plasmid were added to PCR containing equivalent amounts of cDNA, indicated primer pairs and Taq Master Mix (Qiagen). PCR was carried out by denaturing at 95°C for 5 minutes, followed by 25 (GAPDH) or 35 (FCMo3) cycles: 95°C, 30 seconds; 59°C, 30 seconds; and 72°C, 90 seconds, followed by extension at 72°C for 10 minutes. PCR products were separated on a 1% agarose gel and imaged by UV luminescence.
Data Analysis
Gene-chip output files were inspected for artifacts and proper array grid alignment. Data of all experiments were globally normalized using The Equalizer, an application for Windows NT written in Microsoft Visual Basic 6.23 Normalization included linearizing the expression and background correction (98.5%>background). Consistent changes in gene expression due to the high cholesterol diets were identified by nearest neighbors analysis,24 in which the class descriptor was high versus normal cholesterol diet without regard to anatomical location. Genes were prioritized according to the difference between the calculated metric P(g,c) and 100 random permutations of classification. Genes for which significant differences (P<0.05) were detected between control and hypercholesterolemic groups by nearest neighbors analysis and/or Students t test were then further analyzed with GeneSpring 3.2.8 (Silicon Genetics). Lesion sizes in the aortic origin, weights and plasma cholesterol and triglyceride data showed normal distribution and comparisons between groups were performed using Students unpaired t test, assuming unequal variances. Data shown are mean±SEM.
Immunohistochemistry
Sections of the aortic origin were immunostained by an avidin-biotin-alkaline phosphatase (AP) method with a red color substrate21 and counterstained with methyl green. MERG protein was assessed using an affinity-purified rabbit antibody (1:20) to a fusion protein of its human equivalent, HERG, which had a 50/54 amino acid homology to MERG (Alomone Labs). Specificity of staining was verified by competition assays, in which the antibody was preincubated with the antigen. NPAS-2 protein was determined by an affinity-purified rabbit antibody (1 µg/mL) against a 15 amino acid internal peptide sequence of human NPAS-2 (MOP-4) with a 100% homology to mouse NPAS-2 (Alpha Diagnostic International). FGFbp was detected by an antiserum to an affinity-purified recombinant GST-FGFbp fusion protein (1:300 dilution),25,26 a generous gift of Dr A. Wellstein, Georgetown University, Washington, DC.
 |
Results
|
|---|
Both hypercholesterolemic diets markedly raised maternal cholesterol
levels (
Figure 2A). At the beginning of pregnancy, levels in
the 0.075% and 1.25% cholesterol groups were 1063 and 1299 mg/dL,
respectively, compared with approximately 250 mg/dL in the control
group and all groups prior to intervention (
P<0.0001). At
birth, mothers of the hypercholesterolemic groups were switched
to regular chow and within one week maternal cholesterol levels
in all 3 groups were similar (420 to 456 mg/dL). The relative
increase in the control group compared with prepregnancy levels
was reminiscent of increased cholesterol levels during the third
trimester in human mothers.
27 Triglyceride levels showed an
analogous rise to 120 and 124 mg/dL in the 0.075% and 1.25%
cholesterol groups, respectively, compared with 52 mg/dL in
the control group (
P<0.001) (
Figure 2B). Body weights, plasma
cholesterol, and triglycerides in male offspring at 3 months
old are shown in
Table 1. Except for a marginally higher body
weight in the 1.25% cholesterol group than in the 0.075% cholesterol
group, no significant differences were observed. In contrast,
female offspring of the 1.25% cholesterol group had slightly
lower body weight and markedly lower plasma cholesterol levels
then other female groups (data not shown).

View larger version (45K):
[in this window]
[in a new window]
|
Figure 2. Maternal plasma cholesterol (A) and triglyceride levels (B) before the onset of the diet and at the beginning of pregnancy, ie, after 3 weeks on diet. *P<0.0001 vs control.
|
|
The average size of lesions in sections through the aortic origin of male mice is shown in Figure 3. Compared with offspring of control mice, offspring of mothers fed the 0.075% cholesterol diet showed a >2-fold increase in lesions (P<0.00001). Lesions in the 1.25% cholesterol group were also increased, but the difference failed to reach statistical significance (P=0.11). No significant differences in lesion sizes were seen in female offspring (not shown). Representative examples of lesions in offspring of control and hypercholesterolemic mothers are shown in Figures 1A/1B and 1C, respectively.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 3. Extent of atherosclerosis in the aortic origin of male offspring aged 3 months. *P<0.00001; #P=0.11 vs control.
|
|
In contrast to the aortic origin, serial sectioning of the entire aorta (from the heart to the iliac bifurcation) of 2 additional mice from each group revealed only a few adherent monocytes but no intimal thickening. We therefore bypassed tissue embedding, sectioning, and selective harvesting of arterial cells by laser capture microscope.28 Instead, gene expression was determined in aortic segments containing both the media and endothelial monolayer, using Affymetrix microarrays. Altogether, 6 comparisons were performed between the control group and the 2 hypercholesterolemic groups. Gene expression of 11 000 murine genes/ESTs in all experiments was normalized together and statistical differences between the control and hypercholesterolemic groups were established by nearest neighbors analysis24 and t test. Given that both hypercholesterolemic groups showed increased lesions in the aortic arch, we assumed that genes potentially contributing to atherogenesis should be similarly regulated in both hypercholesterolemic groups, compared with controls. Addition of this requirement reduced the number of significant genes to 139, of which 57 were upregulated and 82 downregulated. All significant genes were then entered into GeneSpring, and a gene tree constructed using a pairwise correlation model. The dendrogram indicating clusters of genes with similar patterns of expression is shown in Figure 1D, together with the color-coded mean expression level of each gene. A graphic representation of all up- and downregulated genes and ESTs is shown in Figure 1E. Interestingly, the vast majority of regulated genes showed a greater degree of regulation in the 0.075% cholesterol group than in the 1.25% group, consistent with more extensive lesions in the aortic origin of the former. Changes in gene expression for most genes were smaller than 3-fold and about two thirds did not exceed 1.5-fold up- or downregulation. All known genesbut not the ESTsand their GeneBank accession numbers are listed in Table 2.
Twelve genes showing upregulation in the aorta of mice exposed to fetal hypercholesterolemia were subjected to secondary analysis using semiquantitative PCR. The majority of these genes were expressed at relatively low levels, and for 8 genes, differential expression could not be confirmed within the level of experimental error for semiquantitative PCR. However, semiquantitative PCR analysis of 4 of the 12 transcripts indicated 1.7- to 2.9-fold upregulation (Figure 4), in good agreement with the 1.5- to 2.3-fold changes observed for these genes in the microarray experiments. These transcripts are encoded by the fibroblast growth factor binding protein (FGFbp) gene involved in neovascularization and cancer growth,25 the flavin containing monooxidase 3 gene, the NPAS2 gene,29 and the MERG1 potassium channel gene. Quantitative PCR for one of these genes, FCMo3, performed on RNA from individual mice yielded qualitatively similar results (Table 3). Although 82 genes were found to be downregulated at a statistically significant level by microarray analysis, the fold changes were too small to be reliably detected by semiquantitative PCR.

View larger version (68K):
[in this window]
[in a new window]
|
Figure 4. Semiquantitative PCR confirming the upregulation of selected genes identified by microarray. See Table 2 for details on genes. The degree of upregulation ( fold) was determined by densitometric analysis of bands.
|
|
Because aortas were used for RNA extraction, the presence of proteins in experimental mice was assessed in lesion-free sections of the aortic origin. Immunostaining for 3 of the 4 genes found to be upregulated by PCR indicated that the corresponding proteins were also consistently increased in mice of the 0.075% cholesterol group, compared with controls. NPAS-2 protein was expressed in all endothelium of both groups, but staining intensity was generally stronger and some medial cells also stained in the 0.075% cholesterol group (data not shown). Marked differences between groups were also detected for MERG, which was mainly found in some deep medial areas of the aortic origin (Figures 5A through 5D). FGFbp was not significantly expressed in intimal and medial tissues of the control group, but areas of endothelial staining were frequent in the 0.075% cholesterol group (Figures 5E and 5F).

View larger version (184K):
[in this window]
[in a new window]
|
Figure 5. Immunostaining of the aortic origin of experimental mice for MERG (A through D) and FGFbp (E and F) protein. MERG staining (arrows) in deeper medial areas and the cusps of the aortic valve was consistently stronger in mice of the 0.075% cholesterol group (A and C) than in controls (B). Specificity of MERG staining in C is demonstrated by a serial section stained with the same antibody preincubated with the antigenic peptide (D). Areas of endothelial FGFbp staining were detected only in the 0.075% cholesterol group (E), not the control (F). Final magnification: A through D, 64x; E and F, 198x.
|
|
 |
Discussion
|
|---|
Two main findings emerge from these studies. First, maternal
hypercholesterolemia during pregnancy enhances early atherogenesis
in a genetically uniform murine model. This considerably strengthens
the assumption that the marked increase in fatty streaks seen
in human fetuses of hypercholesterolemic mothers is caused,
at least in part, by hypercholesterolemia and related pathogenic
events during fetal development. The 2-fold increase in lesion
sizes in male offspring of hypercholesterolemic mice was smaller
than that seen in premature human fetuses and term-born NZW
rabbits,
1,5,6 suggesting that some enhancement of lesion formation
already occurred in our mildly hypercholesterolemic control
group compared with truly normocholesterolemic mice. The lack
of a significant effect in female offspring contrasts with results
in humans and rabbits, but several unrelated studies noted analogous
sex differences in mice.
22 Nevertheless, the present experiments
establish a genetically uniform model in which the mechanisms
responsible for fetal atherogenesis and its long-term consequences
can be investigated on the molecular level.
The second finding is that maternal hypercholesterolemia during fetal development affects arterial gene expression or transcription, as well as the respective proteins, later in life. Offspring of both groups of hypercholesterolemic mothers showed statistically significant regulation in the expression of 135 genes and ESTs at 3 months old, compared with offspring of normocholesterolemic mothers. The degree of regulation of most of these genes was modest, consistent with the assumption that genes affecting the susceptibility to postnatal atherogenesis exert their influence by acting over prolonged periods, rather than by displaying dramatic levels of regulation. However, the joint analysis of medial and endothelial cells may also have masked selective regulation of endothelial genes. Differences in endothelial staining for the proteins of some of the regulated genes (FGFbp and NPAS2) are consistent with this assumption. Because all offspring were fed regular chow and had virtually identical plasma lipid levels and because the differences were observed in nonatherosclerotic aortas, the regulation of genes cannot be attributed to acute differences in diet-induced oxidative stress or to differences in lesions formed during fetal development.
In contrast to the situation at 3 months, there is ample reason to postulate short-term changes in the expression of many genes during fetal development. Extensive evidence links maternal hypercholesterolemia to enhanced lipid peroxidation during fetal development. This includes the prevalence of oxidation-specific epitopes in fatty streaks of premature human fetuses1 and term-born rabbits,5,6 increased levels of oxidized lipids in plasma and lesions of rabbits, and the reduction of fetal lesion formation by maternal antioxidant treatment.5,6 Increased lipid peroxidation and formation of reactive oxygen species affects several signaling pathways, including the NF-
B pathway,30 FasL and TNF receptor pathways,1315 and PPAR
,12,31 which regulate expression or transcription of many genes modulating cell recruitment, growth and differentiation, and programmed death.
It can therefore be assumed that multiple genes are up- or downregulated in fetal or neonatal arteries, either as a consequence of acute effects of oxidative stress or secondary to fatty streak formation. What could not be assumed is that pathogenic events during fetal development affect gene expression in morphologically normal aortas much later in life. Microscopic examination of aortas and the lack of regulation of factors traditionally associated with macrophage recruitment, differentiation, or activation suggest that these changes are not the result of differences in intimal lesions. A more likely explanation is that fetal gene modulation results in permanent changes in matrix components, intracellular proteins, enzymes, or DNA. Completely regressed fatty streaks may leave behind similar subtle differences in arterial cells.
Evidence for persistent effects of a brief stimulation during the fetal or neonatal period has been previously reported. For example, enhancement of cholesterol degradation by cholestyramine in neonatal guinea-pigs and very young White Carneau pigeons conveyed a significant protection against dietary hypercholesterolemia in adulthood.32,33 This was associated with an increased level in 7-
-hydroxylase in pretreated adult animals on dietary cholesterol stimulus. Hormonal imprinting in neonatal rats exposed to thyroid stimulating hormone has also been described.34 Interestingly, parental imprinting of the Mas protooncogene also appears to occur during particular stages of fetal development.35
A gene chipbased approach appears particularly attractive to search for evidence of persistent changes in arterial gene regulation. Microarrays have been extensively used for studies of cultured cells, but only recently has their application been extended to cancer36,37 and cardiovascular tissues,38,39 which are greatly complicated by the lack of synchronicity of cell proliferation and differentiation. Tissue heterogeneity may be particularly problematic in atherosclerotic lesions, where macrophages, endothelial cells, smooth muscle cells, and T cells interact. Experimental conditions in this study were chosen to yield descending aortas essentially free of lesions. Indeed, macrophage-specific genes were conspicuously absent, consistent with the lack of foam cells observed in histological sections of the descending aorta. This considerably reduces tissue heterogeneity, but also means that our list was unlikely, a priori, to include many genes expressed in the atherosclerotic intima and contributing to the progression of atherosclerotic lesions. Nevertheless, the list of genes programmed in utero may contain some that influence the susceptibility to postnatal exposure to hypercholesterolemia or other risk factors of atherosclerosis.6
A few of the genes listed in Table 2 are thought to be involved in atherogenesis, such as superoxide dismutase, or neovascularization, such as FGFbp.25 Another gene, NPAS2, has recently been reported to be regulated by nuclear hormone receptors such as RXR
in the vasculature.29 However, most of the genes identified by the microarray experiments have not been previously linked with atherosclerosis.
Although the potential causal role of individual genes remains to be established, the differentially regulated genes identified by these studies provide markers of a "molecular memory" of maternal hypercholesterolemia. Analysis of the mechanisms that control the expression of these genes may provide clues on how hypercholesterolemia or the transient development of fatty streaks results in persistent changes in gene expression or transcription within the artery wall and increased atherogenesis later in life. Comprehensive microarrays containing hybridization targets for all potential murine transcripts should soon be available to facilitate identification of the complete set of genes that are persistently affected by maternal hypercholesterolemia. These arrays may be useful in determining whether patterns of gene expression are normalized in mice lacking candidate effector genes or following maternal treatments that prevent or reduce fetal and postnatal lesion formation, such as cholesterol-lowering or antioxidants.
Insights gained by this the approach may also be of interest with respect to the general question of lesion progression or regression. Both experimental and clinical studies have shown that intense lipid-lowering treatment may result in varying degrees of plaque stabilization or lesion regression. However, to date it is unknown whether such arteries remain more susceptible to future exposure to hypercholesterolemia and therefore require more aggressive preventive measures.
 |
Acknowledgments
|
|---|
This work was supported by grant HL-56989 (La Jolla Specialized
Center of Research in Molecular Medicine and Atherosclerosis).
J.S. Welch was supported by a predoctoral training grant from
the American Heart Association. We thank Dr William Wachsman
for valuable advice on microarrays and their evaluation, Dr
Anton Wellstein for generously providing the antibodies to FGFbp,
and Florencia Casanada, Mercedes Silvestre, and Joe Juliano
for excellent technical assistance.
Received January 28, 2002;
accepted February 5, 2002.
 |
References
|
|---|
1.
Napoli C, DArmiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions.
J Clin Invest. 1997;100:26802690.
2.
Napoli C, Witztum JL, de Nigris F, et al. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation. 1999; 99: 20032010.[Abstract/Full Text]
3.
Cayatte AJ, Ashraf M, Subbiah MT. Morphological and smooth muscle cell phenotypic changes in fetal rabbit aorta during development. Basic Res Cardiol. 1989; 84: 259267.[Medline]
4.
Napoli C, Glass CK, Witztum JL, et al. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999; 354: 12341241.[Medline]
5.
Napoli C, Witztum JL, Calara F, et al. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ Res. 2000; 87: 946952.[Abstract/Full Text]
6.
Palinski W, DArmiento FP, Witztum JL, et al. Maternal hypercholesterolemia and treatment during pregnancy influence the long term progression of atherosclerosis in offspring of rabbits. Circ Res. 2001; 89: 991996.[Abstract/Full Text]
7.
Palinski W, Napoli C, Reaven PD. In: Simons DI, Rogers C, eds. Contemporary Cardiology: Vascular Disease and Injury: Preclinical Research. Totowa, NJ: Humana Press; 2000: 149174.
8.
Palinski W, Napoli C. Pathophysiological events during pregnancy influence the development of atherosclerosis in humans. Trends Cardiovasc Med. 1999; 9: 205214.[Medline]
9.
Napoli C, Palinski W. Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications. Eur Heart J. 2001; 22: 49.[Medline]
10.
Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol. 1998; 10: 248253.[Medline]
11.
Liao F, Andalibi A, Qiao JH, et al. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction and aortic fatty streak formation in mice. J Clin Invest. 1994; 94: 877884.[Medline]
12.
Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPAR
) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:76147619.
13.
Dimmeler S, Haendeler J, Galle J, et al. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases: a mechanistic clue to the response to injury hypothesis. Circulation. 1997; 95: 17601763.[Abstract/Full Text]
14.
Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest. 1998; 102: 16821689.[Abstract/Full Text]
15.
Napoli C, Quehenberger O, de Nigris F, et al. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 2000; 4: 19962007.
16.
de Nigris F, Youssef T, Ciafré SA, et al. Evidence for oxidative activation of c-Mycdependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits: protective effects of vitamin E. Circulation. 2000; 102: 21112117.[Abstract/Full Text]
17.
Schena M, Shalon D, Davis R. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270: 467470.[Abstract]
18.
Duggan DJ, Bittner M, Chen Y, et al. Expression profiling using cDNA microarrays. Nat Genet. 1999; 21 (suppl 1): 1014.[Medline]
19.
Ishibashi S, Goldstein JL, Brown MS, et al. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994; 93: 18851893.[Medline]
20.
Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein Edeficient mice. J Lipid Res. 1995; 36: 23202328.[Abstract]
21.
Palinski W, Tangirala RK, Miller E, et al. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 1995; 15: 15691576.[Abstract/Full Text]
22.
Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor
ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000; 106: 523531.[Abstract/Full Text]
23.
Stuart RO, Bush KT, Nigam SK. Changes in global gene expression patterns during development and maturation of the rat kidney. Proc Natl Acad Sci U S A. 2001;98:56495654.
24.
Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286: 531537.[Abstract/Full Text]
25.
Czubayko F, Liaudet-Coopman ED, Aigner A, et al. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med. 1997; 3: 11371140.[Medline]
26.
Aigner A, Ray PE, Czubayko F, et al. Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem Cell Biol. 2002; 117: 111.[Medline]
27.
Montes A, Walden CE, Knopp RH, et al. Physiologic and supraphysiologic increases in lipoprotein lipids and apoproteins in late pregnancy and postpartum: possible markers for the diagnosis of "prelipemia". Arteriosclerosis. 1984; 4: 407417.[Abstract]
28.
Bonner RF, Emmert-Buck M, Cole K, et al. Laser capture microdissection: molecular analysis of tissue. Science. 1997; 278: 1481148327.[Full Text]
29.
McNamara P, Seo SP, Rudic RD, et al. Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell. 2001; 105: 877889.[Medline]
30.
Mercurio F, Manning AM. Multiple signals converging on NF-
B. Curr Opin Cell Biol. 1999; 11: 226232.[Medline]
31.
Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-
is a negative regulator of macrophage activation. Nature. 1998; 391: 7982.[Medline]
32.
Li JR, Bale LK, Kottke BA. Effect of neonatal modulation of cholesterol homeostasis on subsequent response to cholesterol challenge in adult guinea pig. J Clin Invest. 1980; 65: 10601068.[Medline]
33.
Subbiah MT, Deitemeyer D, Yunker RL. Decreased atherogenic response to dietary cholesterol in pigeons after stimulation of cholesterol catabolism in early life. J Clin Invest. 1983; 71: 15091513.[Medline]
34.
Gruszczynska M, Thang TC, Csaba G. Response to thyroid stimulating hormone in 1-week-old rat thyroid gland after pretreatment the same hormone in newborn conditions (hormonal imprinting). Cytobios. 1993; 74: 167175.[Medline]
35.
Villar AJ, Pedersen RA. Parental imprinting of the Mas protooncogene in mouse. Nat Gen. 1994; 8: 373379.
36.
Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000; 24: 227235.[Medline]
37.
Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A. 1999;96:1326413269.
38.
Stanton LW, Garrard LJ, Damm D, et al. Altered patterns of gene expression in response to myocardial infarction. Circ Res. 2000; 86: 939945.[Abstract/Full Text]
39.
Haley KJ, Lilly CM, Yang JH, et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation. 2000; 102: 21852189.[Abstract/Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
P. Shelley, M. S. Martin-Gronert, A. Rowlerson, L. Poston, S. J. R. Heales, I. P. Hargreaves, J. M. McConnell, S. E. Ozanne, and D. S. Fernandez-Twinn
Altered skeletal muscle insulin signaling and mitochondrial complex II-III linked activity in adult offspring of obese mice
Am J Physiol Regulatory Integrative Comp Physiol,
September 1, 2009;
297(3):
R675 - R681.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. T. Alexander
Developmental programming of sex-dependent alterations in lipid metabolism: a role for long-term, sex-specific alterations in LDL-receptor expression. Focus on "Developmental programming of lipid metabolism and aortic vascular function in C57BL/6 mice: a novel study suggesting an involvement of LDL-receptor"
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 2009;
296(4):
R1027 - R1028.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Decano, J. C. Viereck, A. C. McKee, J. A. Hamilton, N. Ruiz-Opazo, and V. L.M. Herrera
Early-Life Sodium Exposure Unmasks Susceptibility to Stroke in Hyperlipidemic, Hypertensive Heterozygous Tg25 Rats Transgenic for Human Cholesteryl Ester Transfer Protein
Circulation,
March 24, 2009;
119(11):
1501 - 1509.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. K. S. Bhasin, A. van Nas, L. J. Martin, R. C. Davis, S. U. Devaskar, and A. J. Lusis
Maternal Low-Protein Diet or Hypercholesterolemia Reduces Circulating Essential Amino Acids and Leads to Intrauterine Growth Restriction
Diabetes,
March 1, 2009;
58(3):
559 - 566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lanza, N. Cirillo, R. Rossiello, M. Rienzo, L. Cutillo, A. Casamassimi, F. de Nigris, C. Schiano, L. Rossiello, F. Femiano, et al.
Evidence of Key Role of Cdk2 Overexpression in Pemphigus Vulgaris
J. Biol. Chem.,
March 28, 2008;
283(13):
8736 - 8745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.-M. Samuelsson, P. A. Matthews, M. Argenton, M. R. Christie, J. M. McConnell, E. H.J. M. Jansen, A. H. Piersma, S. E. Ozanne, D. F. Twinn, C. Remacle, et al.
Diet-Induced Obesity in Female Mice Leads to Offspring Hyperphagia, Adiposity, Hypertension, and Insulin Resistance: A Novel Murine Model of Developmental Programming
Hypertension,
February 1, 2008;
51(2):
383 - 392.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Palinski and C. Napoli
Impaired Fetal Growth, Cardiovascular Disease, and the Need to Move on
Circulation,
January 22, 2008;
117(3):
341 - 343.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Ashley, J. M. Spin, R. Tabibiazar, and T. Quertermous
Frontiers in Nephrology: Genomic Approaches to Understanding the Molecular Basis of Atherosclerosis
J. Am. Soc. Nephrol.,
November 1, 2007;
18(11):
2853 - 2862.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. E. Alkemade, A. C. Gittenberger-de Groot, A. E. Schiel, J. C. VanMunsteren, B. Hogers, L. S. J. van Vliet, R. E. Poelmann, L. M. Havekes, K. Willems van Dijk, and M. C. DeRuiter
Intrauterine Exposure to Maternal Atherosclerotic Risk Factors Increases the Susceptibility to Atherosclerosis in Adult Life
Arterioscler Thromb Vasc Biol,
October 1, 2007;
27(10):
2228 - 2235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Tassi, S. Walter, A. Aigner, R. H. Cabal-Manzano, R. Ray, P. J. Reier, and A. Wellstein
Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury
Am J Physiol Regulatory Integrative Comp Physiol,
August 1, 2007;
293(2):
R775 - R783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. de Nigris, S. Williams-Ignarro, V. Sica, L. O. Lerman, F. P. D'Armiento, R. E. Byrns, A. Casamassimi, D. Carpentiero, C. Schiano, D. Sumi, et al.
Effects of a Pomegranate Fruit Extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis
Cardiovasc Res,
January 15, 2007;
73(2):
414 - 423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Napoli, L. O. Lerman, F. de Nigris, M. Gossl, M. L. Balestrieri, and A. Lerman
Rethinking Primary Prevention of Atherosclerosis-Related Diseases
Circulation,
December 5, 2006;
114(23):
2517 - 2527.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yamashita, S. Freigang, C. Eberle, J. Pattison, S. Gupta, C. Napoli, and W. Palinski
Maternal Immunization Programs Postnatal Immune Responses and Reduces Atherosclerosis in Offspring
Circ. Res.,
September 29, 2006;
99(7):
E51 - E64.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Napoli, S. Williams-Ignarro, F. de Nigris, L. O. Lerman, F. P. D'Armiento, E. Crimi, R. E. Byrns, A. Casamassimi, A. Lanza, F. Gombos, et al.
Physical training and metabolic supplementation reduce spontaneous atherosclerotic plaque rupture and prolong survival in hypercholesterolemic mice
PNAS,
July 5, 2006;
103(27):
10479 - 10484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.P.J.J. Bijnens, E. Lutgens, T. Ayoubi, J. Kuiper, A.J. Horrevoets, and M.J.A.P. Daemen
Genome-Wide Expression Studies of Atherosclerosis: Critical Issues in Methodology, Analysis, Interpretation of Transcriptomics Data
Arterioscler Thromb Vasc Biol,
June 1, 2006;
26(6):
1226 - 1235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A Woollett
Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation
Am. J. Clinical Nutrition,
December 1, 2005;
82(6):
1155 - 1161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hayashi, P. A. R. Juliet, H. Matsui-Hirai, A. Miyazaki, A. Fukatsu, J. Funami, A. Iguchi, and L. J. Ignarro
L-citrulline and L-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits
PNAS,
September 20, 2005;
102(38):
13681 - 13686.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Armitage, P. D. Taylor, and L. Poston
Experimental models of developmental programming: consequences of exposure to an energy rich diet during development
J. Physiol.,
May 15, 2005;
565(1):
3 - 8.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Napoli, O. Pignalosa, F. de Nigris, and V. Sica
Childhood Infection and Endothelial Dysfunction: A Potential Link in Atherosclerosis?
Circulation,
April 5, 2005;
111(13):
1568 - 1570.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. de Nigris, S. Williams-Ignarro, L. O. Lerman, E. Crimi, C. Botti, G. Mansueto, F. P. D'Armiento, G. De Rosa, V. Sica, L. J. Ignarro, et al.
Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress
PNAS,
March 29, 2005;
102(13):
4896 - 4901.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Yang, C. A. Knight, M. M. Mamerow, K. Vickers, A. Penn, E. M. Postlethwait, and S. W. Ballinger
Prenatal Environmental Tobacco Smoke Exposure Promotes Adult Atherogenesis and Mitochondrial Damage in Apolipoprotein E-/- Mice Fed a Chow Diet
Circulation,
December 14, 2004;
110(24):
3715 - 3720.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kitajka, A. J. Sinclair, R. S. Weisinger, H. S. Weisinger, M. Mathai, A. P. Jayasooriya, J. E. Halver, and L. G. Puskas
Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression
PNAS,
July 27, 2004;
101(30):
10931 - 10936.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Napoli, S. Williams-Ignarro, F. de Nigris, L. O. Lerman, L. Rossi, C. Guarino, G. Mansueto, F. Di Tuoro, O. Pignalosa, G. De Rosa, et al.
Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice
PNAS,
June 8, 2004;
101(23):
8797 - 8802.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Yokoyama, H. Yagyu, Y. Hu, T. Seo, K. Hirata, S. Homma, and I. J. Goldberg
Apolipoprotein B Production Reduces Lipotoxic Cardiomyopathy: STUDIES IN HEART-SPECIFIC LIPOPROTEIN LIPASE TRANSGENIC MOUSE
J. Biol. Chem.,
February 6, 2004;
279(6):
4204 - 4211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. VanderLaan, C. A. Reardon, and G. S. Getz
Site Specificity of Atherosclerosis: Site-Selective Responses to Atherosclerotic Modulators
Arterioscler Thromb Vasc Biol,
January 1, 2004;
24(1):
12 - 22.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. P. Sorescu, M. Sykes, D. Weiss, M. O. Platt, A. Saha, J. Hwang, N. Boyd, Y. C. Boo, J. D. Vega, W. R. Taylor, et al.
Bone Morphogenic Protein 4 Produced in Endothelial Cells by Oscillatory Shear Stress Stimulates an Inflammatory Response
J. Biol. Chem.,
August 15, 2003;
278(33):
31128 - 31135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A.C. 't Hoen, C. A.C. Van der Lans, M. Van Eck, M. K. Bijsterbosch, T. J.C. Van Berkel, and J. Twisk
Aorta of ApoE-Deficient Mice Responds to Atherogenic Stimuli by a Prelesional Increase and Subsequent Decrease in the Expression of Antioxidant Enzymes
Circ. Res.,
August 8, 2003;
93(3):
262 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Y. Liu, A. K. Death, and D. J. Handelsman
Androgens and Cardiovascular Disease
Endocr. Rev.,
June 1, 2003;
24(3):
313 - 340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Napoli, L O Lerman, V Sica, A Lerman, G Tajana, and F de Nigris
Microarray analysis: a novel research tool for cardiovascular scientists and physicians
Heart,
June 1, 2003;
89(6):
597 - 604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Napoli, I. Martin-Padura, F. de Nigris, M. Giorgio, G. Mansueto, P. Somma, M. Condorelli, G. Sica, G. De Rosa, and P. Pelicci
Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet
PNAS,
February 18, 2003;
100(4):
2112 - 2116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. W Shaul
Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis
J. Physiol.,
February 15, 2003;
547(1):
21 - 33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. de Nigris, L. O. Lerman, S. W. Ignarro, G. Sica, A. Lerman, W. Palinski, L. J. Ignarro, and C. Napoli
From the Cover: Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress
PNAS,
February 4, 2003;
100(3):
1420 - 1425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Palinski and C. Napoli
Unraveling Pleiotropic Effects of Statins on Plaque Rupture
Arterioscler Thromb Vasc Biol,
November 1, 2002;
22(11):
1745 - 1750.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Napoli, E. Ackah, F. de Nigris, P. Del Soldato, F. P. D'Armiento, E. Crimi, M. Condorelli, and W. C. Sessa
Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice
PNAS,
September 17, 2002;
99(19):
12467 - 12470.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. PALINSKI and C. NAPOLI
The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis
FASEB J,
September 1, 2002;
16(11):
1348 - 1360.
[Abstract]
[Full Text]
[PDF]
|
 |
|